Clinical Trial Update: A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC [Phase 3]

View source ↗

Summary

Phase 3 randomized trial evaluating HLX10 plus carboplatin-nab-paclitaxel vs placebo for first-line treatment inStage IIIB/IIIC or IV non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Non-small Cell Lung Cancer

Drugs mentioned

• Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel (Carboplatin-Nab-paclitaxel)
• HLX10

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Squamous Non Small Cell Lung Cancer | Phase 3 | Status: UNKNOWN